MedTrace Logo

Treatment of Hypertension in Tibetan Adult Population

NCT02217852 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2014-08-29

No results posted yet for this study

Summary

Several surveys had revealed that Tibetan adults had high prevalence of hypertension. However, there was no research studying the antihypertensive effect of the known drugs in Tibetan. The main arms of our study were to determine if the efficacy of lowing blood pressure and protecting target organ damage differs between nitrendipine and Hydrochlorothiazide in mild hypertension in Tibetan, and to determine if the efficacy of lowing blood pressure and protecting target organ damage differs between captopril plus Hydrochlorothiazide and Beijing hypotensive No.0 in moderate and severe Tibetan hypertension.

Conditions

Interventions

DRUG

Nitrendipine

doses used range from 10-20mg po bid. Total duration would be until completion or study or medication intolerance.

DRUG

Hydrochlorothiazide

doses used range from 12.5-25mg po qd. Total duration would be until completion or study or medication intolerance.

DRUG

Captopril,Hydrochlorothiazide

doses used range from 25-50mg po tid for captopril and 12.5-25mg po qd for hydrochlorothiazide. Total duration would be until completion or study or medication intolerance.

DRUG

Beijing hypotensive No.0

1 pile po qd or less. Total duration would be until completion or study or medication intolerance.

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Principal Investigators

  • Xiaoping Chen, MD · West China Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2016-01-31
Completion
2016-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02217852 on ClinicalTrials.gov